Intrinsic value of IDEXX Laboratories - IDXX

Previous Close

$190.01

  Intrinsic Value

$80.62

stock screener

  Rating & Target

str. sell

-58%

Previous close

$190.01

 
Intrinsic value

$80.62

 
Up/down potential

-58%

 
Rating

str. sell

We calculate the intrinsic value of IDXX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 16.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  14.10
  13.19
  12.37
  11.63
  10.97
  10.37
  9.84
  9.35
  8.92
  8.53
  8.17
  7.86
  7.57
  7.31
  7.08
  6.87
  6.69
  6.52
  6.37
  6.23
  6.11
  6.00
  5.90
  5.81
  5.73
  5.65
  5.59
  5.53
  5.48
  5.43
Revenue, $m
  2,247
  2,543
  2,858
  3,190
  3,540
  3,907
  4,292
  4,693
  5,111
  5,547
  6,001
  6,472
  6,962
  7,471
  8,000
  8,550
  9,122
  9,716
  10,335
  10,979
  11,649
  12,347
  13,075
  13,835
  14,627
  15,454
  16,317
  17,219
  18,162
  19,148
Variable operating expenses, $m
  1,515
  1,712
  1,921
  2,141
  2,374
  2,617
  2,872
  3,139
  3,416
  3,706
  3,982
  4,295
  4,620
  4,958
  5,309
  5,674
  6,053
  6,448
  6,858
  7,286
  7,731
  8,194
  8,677
  9,181
  9,707
  10,255
  10,828
  11,427
  12,053
  12,707
Fixed operating expenses, $m
  235
  240
  246
  251
  256
  262
  268
  274
  280
  286
  292
  299
  305
  312
  319
  326
  333
  340
  348
  355
  363
  371
  379
  388
  396
  405
  414
  423
  432
  442
Total operating expenses, $m
  1,750
  1,952
  2,167
  2,392
  2,630
  2,879
  3,140
  3,413
  3,696
  3,992
  4,274
  4,594
  4,925
  5,270
  5,628
  6,000
  6,386
  6,788
  7,206
  7,641
  8,094
  8,565
  9,056
  9,569
  10,103
  10,660
  11,242
  11,850
  12,485
  13,149
Operating income, $m
  496
  591
  691
  798
  910
  1,028
  1,151
  1,281
  1,415
  1,556
  1,726
  1,878
  2,037
  2,201
  2,372
  2,550
  2,735
  2,928
  3,129
  3,338
  3,555
  3,782
  4,019
  4,266
  4,524
  4,793
  5,075
  5,369
  5,677
  5,999
EBITDA, $m
  597
  702
  813
  931
  1,055
  1,186
  1,322
  1,465
  1,614
  1,770
  1,931
  2,100
  2,275
  2,456
  2,646
  2,842
  3,047
  3,260
  3,482
  3,713
  3,953
  4,204
  4,466
  4,739
  5,024
  5,321
  5,632
  5,958
  6,298
  6,653
Interest expense (income), $m
  32
  68
  67
  79
  91
  104
  118
  133
  148
  163
  180
  197
  215
  233
  253
  273
  293
  315
  337
  361
  385
  410
  437
  464
  493
  522
  553
  586
  620
  655
  692
Earnings before tax, $m
  428
  523
  612
  706
  805
  910
  1,019
  1,133
  1,252
  1,376
  1,529
  1,664
  1,803
  1,949
  2,100
  2,257
  2,420
  2,591
  2,768
  2,953
  3,145
  3,346
  3,555
  3,773
  4,001
  4,240
  4,489
  4,749
  5,022
  5,307
Tax expense, $m
  116
  141
  165
  191
  217
  246
  275
  306
  338
  371
  413
  449
  487
  526
  567
  609
  654
  699
  747
  797
  849
  903
  960
  1,019
  1,080
  1,145
  1,212
  1,282
  1,356
  1,433
Net income, $m
  313
  382
  447
  516
  588
  664
  744
  827
  914
  1,004
  1,116
  1,214
  1,316
  1,422
  1,533
  1,648
  1,767
  1,891
  2,021
  2,155
  2,296
  2,442
  2,595
  2,755
  2,921
  3,095
  3,277
  3,467
  3,666
  3,874

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,815
  2,054
  2,308
  2,577
  2,859
  3,156
  3,467
  3,791
  4,129
  4,481
  4,847
  5,228
  5,624
  6,035
  6,462
  6,906
  7,368
  7,848
  8,348
  8,868
  9,410
  9,974
  10,562
  11,175
  11,815
  12,483
  13,180
  13,909
  14,671
  15,467
Adjusted assets (=assets-cash), $m
  1,815
  2,054
  2,308
  2,577
  2,859
  3,156
  3,467
  3,791
  4,129
  4,481
  4,847
  5,228
  5,624
  6,035
  6,462
  6,906
  7,368
  7,848
  8,348
  8,868
  9,410
  9,974
  10,562
  11,175
  11,815
  12,483
  13,180
  13,909
  14,671
  15,467
Revenue / Adjusted assets
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
  1.238
Average production assets, $m
  553
  626
  703
  785
  871
  961
  1,056
  1,154
  1,257
  1,365
  1,476
  1,592
  1,713
  1,838
  1,968
  2,103
  2,244
  2,390
  2,542
  2,701
  2,866
  3,037
  3,217
  3,403
  3,598
  3,802
  4,014
  4,236
  4,468
  4,711
Working capital, $m
  171
  193
  217
  242
  269
  297
  326
  357
  388
  422
  456
  492
  529
  568
  608
  650
  693
  738
  785
  834
  885
  938
  994
  1,051
  1,112
  1,174
  1,240
  1,309
  1,380
  1,455
Total debt, $m
  1,249
  1,465
  1,693
  1,935
  2,189
  2,456
  2,736
  3,028
  3,332
  3,649
  3,978
  4,321
  4,677
  5,047
  5,432
  5,832
  6,247
  6,679
  7,129
  7,597
  8,084
  8,592
  9,121
  9,673
  10,249
  10,850
  11,478
  12,134
  12,820
  13,536
Total liabilities, $m
  1,633
  1,849
  2,077
  2,319
  2,574
  2,841
  3,120
  3,412
  3,716
  4,033
  4,362
  4,705
  5,061
  5,431
  5,816
  6,216
  6,631
  7,064
  7,513
  7,981
  8,469
  8,976
  9,506
  10,057
  10,633
  11,235
  11,862
  12,518
  13,204
  13,920
Total equity, $m
  181
  205
  231
  258
  286
  316
  347
  379
  413
  448
  485
  523
  562
  603
  646
  691
  737
  785
  835
  887
  941
  997
  1,056
  1,117
  1,181
  1,248
  1,318
  1,391
  1,467
  1,547
Total liabilities and equity, $m
  1,814
  2,054
  2,308
  2,577
  2,860
  3,157
  3,467
  3,791
  4,129
  4,481
  4,847
  5,228
  5,623
  6,034
  6,462
  6,907
  7,368
  7,849
  8,348
  8,868
  9,410
  9,973
  10,562
  11,174
  11,814
  12,483
  13,180
  13,909
  14,671
  15,467
Debt-to-equity ratio
  6.880
  7.130
  7.340
  7.510
  7.660
  7.780
  7.890
  7.990
  8.070
  8.140
  8.210
  8.270
  8.320
  8.360
  8.410
  8.440
  8.480
  8.510
  8.540
  8.570
  8.590
  8.610
  8.640
  8.660
  8.670
  8.690
  8.710
  8.720
  8.740
  8.750
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  313
  382
  447
  516
  588
  664
  744
  827
  914
  1,004
  1,116
  1,214
  1,316
  1,422
  1,533
  1,648
  1,767
  1,891
  2,021
  2,155
  2,296
  2,442
  2,595
  2,755
  2,921
  3,095
  3,277
  3,467
  3,666
  3,874
Depreciation, amort., depletion, $m
  101
  111
  122
  133
  145
  158
  171
  185
  199
  214
  205
  221
  238
  255
  273
  292
  312
  332
  353
  375
  398
  422
  447
  473
  500
  528
  558
  588
  621
  654
Funds from operations, $m
  414
  493
  569
  649
  733
  822
  915
  1,012
  1,113
  1,218
  1,321
  1,436
  1,554
  1,678
  1,806
  1,940
  2,079
  2,223
  2,374
  2,530
  2,694
  2,864
  3,042
  3,227
  3,421
  3,623
  3,834
  4,055
  4,287
  4,528
Change in working capital, $m
  21
  23
  24
  25
  27
  28
  29
  31
  32
  33
  34
  36
  37
  39
  40
  42
  43
  45
  47
  49
  51
  53
  55
  58
  60
  63
  66
  69
  72
  75
Cash from operations, $m
  393
  471
  545
  624
  707
  794
  885
  981
  1,081
  1,185
  1,287
  1,400
  1,517
  1,639
  1,766
  1,898
  2,035
  2,178
  2,327
  2,482
  2,643
  2,811
  2,986
  3,170
  3,361
  3,560
  3,769
  3,987
  4,215
  4,453
Maintenance CAPEX, $m
  -67
  -77
  -87
  -98
  -109
  -121
  -133
  -147
  -160
  -175
  -190
  -205
  -221
  -238
  -255
  -273
  -292
  -312
  -332
  -353
  -375
  -398
  -422
  -447
  -473
  -500
  -528
  -558
  -588
  -621
New CAPEX, $m
  -67
  -73
  -77
  -82
  -86
  -90
  -95
  -99
  -103
  -107
  -112
  -116
  -121
  -125
  -130
  -135
  -141
  -146
  -152
  -158
  -165
  -172
  -179
  -187
  -195
  -203
  -212
  -222
  -232
  -243
Cash from investing activities, $m
  -134
  -150
  -164
  -180
  -195
  -211
  -228
  -246
  -263
  -282
  -302
  -321
  -342
  -363
  -385
  -408
  -433
  -458
  -484
  -511
  -540
  -570
  -601
  -634
  -668
  -703
  -740
  -780
  -820
  -864
Free cash flow, $m
  258
  321
  381
  444
  512
  583
  657
  736
  818
  903
  986
  1,079
  1,175
  1,276
  1,381
  1,489
  1,602
  1,720
  1,843
  1,970
  2,103
  2,241
  2,386
  2,536
  2,693
  2,857
  3,028
  3,207
  3,395
  3,590
Issuance/(repayment) of debt, $m
  -12
  215
  229
  242
  254
  267
  279
  292
  304
  317
  330
  343
  356
  370
  385
  400
  416
  432
  450
  468
  487
  508
  529
  552
  576
  601
  628
  656
  686
  717
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -12
  215
  229
  242
  254
  267
  279
  292
  304
  317
  330
  343
  356
  370
  385
  400
  416
  432
  450
  468
  487
  508
  529
  552
  576
  601
  628
  656
  686
  717
Total cash flow (excl. dividends), $m
  246
  537
  609
  686
  766
  850
  937
  1,028
  1,122
  1,220
  1,315
  1,421
  1,532
  1,646
  1,765
  1,889
  2,018
  2,152
  2,292
  2,438
  2,590
  2,749
  2,915
  3,088
  3,269
  3,458
  3,656
  3,863
  4,080
  4,307
Retained Cash Flow (-), $m
  -236
  -24
  -25
  -27
  -28
  -30
  -31
  -32
  -34
  -35
  -37
  -38
  -40
  -41
  -43
  -44
  -46
  -48
  -50
  -52
  -54
  -56
  -59
  -61
  -64
  -67
  -70
  -73
  -76
  -80
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  10
  513
  584
  659
  738
  820
  906
  995
  1,088
  1,185
  1,279
  1,383
  1,492
  1,605
  1,722
  1,845
  1,972
  2,104
  2,242
  2,386
  2,536
  2,693
  2,856
  3,027
  3,205
  3,391
  3,586
  3,790
  4,004
  4,227
Discount rate, %
  6.80
  7.14
  7.50
  7.87
  8.27
  8.68
  9.11
  9.57
  10.05
  10.55
  11.08
  11.63
  12.21
  12.82
  13.46
  14.14
  14.84
  15.59
  16.37
  17.18
  18.04
  18.94
  19.89
  20.89
  21.93
  23.03
  24.18
  25.39
  26.66
  27.99
PV of cash for distribution, $m
  10
  447
  470
  487
  496
  498
  492
  479
  460
  435
  403
  369
  334
  296
  259
  222
  188
  155
  126
  100
  78
  59
  44
  32
  23
  16
  10
  7
  4
  3
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

FINANCIAL RATIOS  of  IDEXX Laboratories (IDXX)

Valuation Ratios
P/E Ratio 75.3
Price to Sales 9.4
Price to Book -154.8
Price to Tangible Book
Price to Cash Flow 49.9
Price to Free Cash Flow 61.9
Growth Rates
Sales Growth Rate 10.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -21.7%
Cap. Spend. - 3 Yr. Gr. Rate -3.8%
Financial Strength
Quick Ratio 1
Current Ratio 0
LT Debt to Equity -462%
Total Debt to Equity -1027.8%
Interest Coverage 11
Management Effectiveness
Return On Assets 16.2%
Ret/ On Assets - 3 Yr. Avg. 15.2%
Return On Total Capital 22.3%
Ret/ On T. Cap. - 3 Yr. Avg. 20%
Return On Equity -231.3%
Return On Equity - 3 Yr. Avg. 318.5%
Asset Turnover 1.2
Profitability Ratios
Gross Margin 54.9%
Gross Margin - 3 Yr. Avg. 55.1%
EBITDA Margin 24.3%
EBITDA Margin - 3 Yr. Avg. 22.9%
Operating Margin 19.7%
Oper. Margin - 3 Yr. Avg. 18.6%
Pre-Tax Margin 18.1%
Pre-Tax Margin - 3 Yr. Avg. 17.3%
Net Profit Margin 12.5%
Net Profit Margin - 3 Yr. Avg. 12.2%
Effective Tax Rate 31.1%
Eff/ Tax Rate - 3 Yr. Avg. 29%
Payout Ratio 0%

IDXX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the IDXX stock intrinsic value calculation we used $1969.058 million for the last fiscal year's total revenue generated by IDEXX Laboratories. The default revenue input number comes from 0001 income statement of IDEXX Laboratories. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our IDXX stock valuation model: a) initial revenue growth rate of 14.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6.8%, whose default value for IDXX is calculated based on our internal credit rating of IDEXX Laboratories, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of IDEXX Laboratories.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of IDXX stock the variable cost ratio is equal to 67.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $230 million in the base year in the intrinsic value calculation for IDXX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for IDEXX Laboratories.

Corporate tax rate of 27% is the nominal tax rate for IDEXX Laboratories. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the IDXX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for IDXX are equal to 24.6%.

Life of production assets of 7.2 years is the average useful life of capital assets used in IDEXX Laboratories operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for IDXX is equal to 7.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-54.106 million for IDEXX Laboratories - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 86.863 million for IDEXX Laboratories is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of IDEXX Laboratories at the current share price and the inputted number of shares is $16.5 billion.

RELATED COMPANIES Price Int.Val. Rating
HSKA Heska 98.91 18.34  str.sell
TMO Thermo Fisher 235.86 199.97  hold
ZTS Zoetis 88.09 74.54  hold
PDCO Patterson 22.87 30.68  buy
DHR Danaher 101.87 86.30  hold
HSIC Henry Schein 85.16 88.84  hold
ICCC Immucell 7.48 1.06  str.sell

COMPANY NEWS

▶ Do Hedge Funds Love IDEXX Laboratories, Inc. (IDXX)?   [Dec-10-18 12:52AM  Insider Monkey]
▶ IDEXX Lets the 2019 Cat Out of the Bag   [10:13AM  Motley Fool]
▶ Ron Baron Comments on IDEXX Laboratories   [Nov-02-18 03:44PM  GuruFocus.com]
▶ Idexx: 3Q Earnings Snapshot   [06:49AM  Associated Press]
▶ Cramer's 5 health-care stocks he likes right now   [Oct-16-18 07:22PM  CNBC Videos]
▶ Putting IDEXX Laboratories Stock Under the Microscope   [Oct-12-18 12:05PM  TheStreet.com]
▶ Beaten-down tech stocks ripe for the picking   [Oct-11-18 07:14PM  CNBC Videos]
▶ 10 High-Margin Stocks To Survive The U.S.-China Trade War   [Oct-01-18 01:30PM  Investopedia]
▶ 3 Hidden Gems in the Nasdaq-100   [Sep-11-18 10:40AM  Investopedia]
▶ Nasdaq ETF Hits New Highs: 5 Stocks Up More Than 50%   [Aug-28-18 03:07PM  InvestorPlace]
▶ IBD 50 Stocks To Watch: Idexx Stock, Up 56% This Year, Poised For Breakout   [Aug-16-18 04:55PM  Investor's Business Daily]
▶ Oppenheimer Funds Standout Wins With Diversified Portfolio   [10:22AM  Investor's Business Daily]
▶ IDEXX Laboratories Is Not Responding to Bullish News   [Aug-09-18 02:16PM  TheStreet.com]
▶ IDEXX Laboratories to Host 2018 Investor Day   [Aug-06-18 02:00PM  PR Newswire]
▶ Idexx: 2Q Earnings Snapshot   [06:39AM  Associated Press]
▶ The 6 Stocks on the MFM Team's Radar This Week   [Jun-19-18 07:20AM  Motley Fool]
▶ Idexx: Putting Man's Best Friend In A 'Spectacular Industry'?   [May-25-18 12:56PM  Investor's Business Daily]
▶ IDEXX Laboratories Barks Out Another Successful Quarter   [May-11-18 04:47PM  Motley Fool]
▶ The 3 Stocks on the MFM Team's Radar This Week   [May-09-18 08:59PM  Motley Fool]
▶ Apple Leads Five Hot Stocks Now In Buy Range   [May-07-18 04:03PM  Investor's Business Daily]
▶ This Top Medical Stock Breaks Out After Its Beat-And-Raise   [May-04-18 04:58PM  Investor's Business Daily]
▶ Idexx: 1Q Earnings Snapshot   [06:54AM  Associated Press]
▶ Edited Transcript of IDXX presentation 6-Mar-17 3:25pm GMT   [Apr-10-18 03:02PM  Thomson Reuters StreetEvents]
▶ 5 Top-Performing S&P 500 Stocks of Q1   [Mar-29-18 08:29AM  Zacks]
▶ IDEXX Laboratories to Present at Two Conferences   [Feb-15-18 02:30PM  PR Newswire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.